Abstract: Objective Brain metastasis was the main reason for the death of non-small cell lung cancer (non-small cell lung cancer, NSCLC). This study retrospectively analyzed the clinical efficacy and prognostic factors of arterial interventional therapy combined with epidermal growth factor receptor (epidermal growth factor receptor, EGFR)and tyrosine kinase inhibitors (tyrosine kinase inhibitors, TKI) erlotinib (erlotinib) Method Form January 2009 to January 2012,45 NSCLC patients with brain metastasis confirmed by pathology or cytology were collected in our study. They all underwent infusion chemotherapy two-six cycles by selective bronchial artery or intracranial arterial. Erlotinib was used simultaneously or sequentially with the infusion chemotherapy.We assessed the clinical efficacy every two cycles or when the disease got progressed. Results All the patients received at least two cycles of treatment.The median number of cycles was 3(range 1-6). The results were as follows: complete remission (CR) 7 cases (15.56%), partial remission (PR) 12 cases (26.67%), stable (SD) 16 cases (35.56%), progression (PD) 10 cases (22.22%).The objective response rate (ORR, CR + PR) and disease control rate (DCR, CR + PR + SD) was 42.22% and 77.78% respectively. 45 cases of patients with progression-free survival (PFS) time of 7-29 months, the median PFS time was 11.00 months，the overall survival time was 9-44 months, the median OS was 17.00 months. Univariate analysis showed that patients with low PS score has longer PFS than those with higher PS score，patients with low PS score has longer OS than those with higher PS score. Conclusion Arterial interventional therapy combined with erlotinib has got a better short-term effect and prolonged the survival time but with mild side effects. It would be a useful treatment for NSCLC patients with brain metastasis.

Key words: Non-small cell lung cancer, Brain metastasis, Arterial intervention, Erlotinib, Term efficacy, Survival analysis